RxDoctor Payments Data

Gladys Velarde, MD

Cardiovascular Disease · Jacksonville, FLNPI 1720024508

Payments from drug & device makers

$18,385in general payments, 2019–2025

Across 12 payments — averaging $1532.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$15K
  • Amgen$2K
  • Pfizer$1K
  • Abbott$179
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$52
  • Novo Nordisk$48
  • plus $4 from 1 others

What the payments were for

  • Consulting fees$1,78553%
  • Speaking & faculty fees$1,00030%
  • Food & beverage$60018%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,385 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$44,187
Medicare patients
415
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin65$46,832
EliquisApixaban51$44,485
EntrestoSacubitril/Valsartan23$25,337
FarxigaDapagliflozin Propanediol21$19,150
WegovySemaglutide14$18,546
XareltoRivaroxaban12$13,387
OzempicSemaglutide15$12,356
VascepaIcosapent Ethyl16$4,549
Nitroglycerin19$2,809
Ezetimibe65$1,625
Atorvastatin Calcium134$1,528
Metoprolol Succinate68$1,282
Dilt-XrDiltiazem Hcl11$894
Omega-3 Acid Ethyl Esters12$851
Carvedilol56$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,202$44,48551 claims
Novo NordiskWegovy, Ozempic$48$30,90229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →